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Abstract
Bone is a dynamic tissue that undergoes formation, degradation, and repair in a constant state of
remodeling. Bone remodeling is performed and regulated by three cell types: osteoblasts,
osteocytes, and osteoclasts. Bone homeostasis, the balance of bone formation and resorption, is
regulated by biologically active substances secreted by the three bone cell types, as well as
circulating hormones and proteins in the body. Insulin is the main anabolic hormone in the body,
and its effects on bone homeostasis and regulation are still being uncovered. Magnesium is a
trace element that is critical to bone homeostasis. It affects the secretion of hormones that
regulate bone cell function and affects structural formation of mineralized bone. However, the
exact effects of magnesium on bone cells, as well as ideal concentrations of magnesium in the
body are still being elucidated. In this research, we hypothesized that insulin or magnesium
would have dose-dependent positive effect on bone formation in a 3D model, based on current
knowledge regarding both substances. To evaluate this hypothesis, 3D model bone organoids
were developed and treated with increasing doses of insulin or magnesium chloride for 21 days.
Spent cell media was collected at 7, 14, and 21 days of post-treatment to evaluate osteoblast and
osteoclast function via alkaline phosphatase activity and CTX-liberation, respectively. Bone
organoids were harvested at days 14 and 21 to evaluate COX-2 protein expression and calcium
deposition. Our data shows that insulin and magnesium showed some dose-dependent effects on
osteoblast activity. Overall, our data shows that the effects of insulin and magnesium may differ
in a 3D organoid model compared to a 2D monoculture or in vivo conditions, which is important
to establish for future research using 3D organoid models to evaluate these key substances.
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Introduction
Bone Basics
Bone tissue is built from multiple cell types derived from various origins. Bone cells
differentiate in response to different signals. There are three main cell types in bone tissue:
osteoblasts (OBs), osteocytes, and osteoclasts (OCs). Undifferentiated osteoprogenitor cells
differentiate into OBs. Osteoblasts synthesize and secrete the extracellular matrix proteins that
form bone in a process called ossification. As osteoblasts mature and become trapped in the bone
matrix, they differentiate into osteocytes. Osteocytes do not secrete matrix but play an integral
role in maintaining bone tissue. Osteoclasts are fused monocytes specific to bone. OCs are
responsible for bone matrix degradation, a process known as resorption. When OBs and OCs are
properly regulated, bone homeostasis can be established (Zaidi et al., 2018).
Bone Homeostasis
Bone homeostasis is considered a dynamic state where bone undergoes continual
remodeling to maintain its mechanical strength and mineral balance. Bone is formed when
mesenchymal precursors differentiate into osteoblasts (OBs). OBs produce a variety of
extracellular proteins, such as type I collagen, alkaline phosphatase, and osteocalcin, that form
the bone matrix. This extracellular bone matrix is mineralized as hydroxyapatite, a form of
calcium phosphate, that accumulates within the matrix. Osteocytes (OCs) are embedded in the
mature bone where they regulate mineral deposition and produce endocrine signaling molecules.
Hematopoietic stem cells differentiate into OCs, which are typically found at the periphery of the
bone (Kim et al., 2020). In skeletal homeostasis, bone remodeling is regulated by OB bone
formation and OC bone resorption, with no net gain or loss of bone (Kolb and Bussard, 2019).
OBs, OCs, and osteocytes engage in crosstalk between themselves as well as communicating to a
1

host of non-bone cells within bone marrow, including adipocytes, macrophages, hematopoietic
progenitors, and T and B cells (Zaidi et al., 2018). Given this crosstalk using co-culture models
that can mimic some of the complexities of bone are critically important in research.
Osteoblasts
In this 3D model, bone formation is formed mimicking the intramembranous mechanism
of bone formation in vivo. In intramembranous bone formation, immature mesenchymal cells
differentiate into OBs which directly deposit mineralized matrix (Ono et al. 2019). Preosteoblasts
express collagen type I which can be used to assess levels of preosteoblasts and osteoblasts.
Preosteoblasts differentiate into mature osteoblasts in the presence of components of the Wnt
signaling pathway such as Runx2 and osterix (Robling et al., 2006). However, the exact
mechanisms controlling osteoblast differentiation are not fully understood. When preosteoblasts
differentiate into osteoblasts, proliferation is inhibited, and osteoblasts are unable to undergo
mitotic division (Zouani et al., 2013)(Feehan et al., 2018). Mature osteoblasts express collagen
type I (Col-I), as well as osteocalcin, Runx2, and alkaline phosphatase (Robling et al., 2006). All
of these can be used as markers to assess osteoblast function and differentiation. Osteoblasts
synthesize and secrete bone extracellular matrix, called osteoid, in a process termed ossification.
Zouani et al. used the expression of Col-I and Runx2 to characterize osteoblasts in a 2D in vitro
model and found that both markers increased substantially when osteoblast precursors developed
into mature osteoblasts in the presence of BMP-2 (Zouani et al., 2013). In addition to the bone
matrix, osteoblasts also form collagen fibers. When these collagen fibers are degraded, collagen
crosslink peptide fragments, such as C-terminal telopeptide of type I collagen (CTX-1) are
released into serum. Since CTX-1 levels are related to bone resorption they are an excellent way
to measure bone resorption or OC activity in various bone models.
2

Osteoclasts
Hematopoietic stem cells (HSCs) usually found in the bone marrow, liver, and spleen are
the origin cells of osteoclasts. When stimulated by macrophage colony stimulating factor (MCSF), HSCs become mononuclear cells. In the continued presence of M-CSF, the mononuclear
cells differentiate into preosteoclasts. When preosteoclasts fuse together, they form an immature
multi-nucleated osteoclast. Immature osteoclast formation relies on M-CSF as well as the
receptor activator nuclear factor kB ligand (RANKL). JNK and p38 signaling molecules are
involved in RANKL-guided osteoclast differentiation (Amcheslavsky and Bar-Shavit, 2007).
Immature osteoclasts express calcitonin receptors, tartrate-resistant acid phosphatase (TRAP),
and beta-3 integrin. Calcitonin receptors receive calcitonin secreted by osteoblasts and (in vivo)
the thyroid gland, which inhibits osteoclastic resorption. TRAP is used in mature osteoclasts to
support bone resorption and can be used as an additional bone resorption marker. RANKL
regulates bone resorption activity and cell survival in mature osteoclasts (Robling et al., 2006).

Osteocytes

Osteocytes act as mechanical sensors in the bone matrix and send signals to osteoblasts
and osteoclasts. Additionally, osteocytes have endocrine function and secrete components that
affect osteoblast and osteoclasts and control the bone microenvironment. Osteocytes secrete
sclerostin, which inhibits Wnt signaling, thereby negatively regulating OB differentiation and
survival (Wijenayaka et al.). Wnt signaling regulates cell proliferation and differentiation. An in
vitro study by Cai et al. and an in vivo murine study by Minear et al. in a murine both
demonstrated that activation of the Wnt pathway in progenitor cells and in preosteoblasts
increased the rate and amount of osteoblast differentiation and bone formation (Minear et al.,
2010). Wnt signaling in osteocytes regulates bone formation and resorption (Goldring and
3

Goldring, 2007)(Baron and Kneissel, 2013), as Wnt signaling inhibits osteoclastogenesis and
resulting resorption, as well as stimulates osteoblasts and osteocytes which enhances bone
formation (Goldring and Goldring, 2007). A study by Zhou, Lin, et al showed that activation of
Wnt signaling negatively affected levels of osteocyte markers, for example dentin matrix protein
1, bone mineralization was also affected. Wnt signaling in osteocytes has been shown to directly
cause OB differentiation. (Liu et al., 2022). Further, as demonstrated by Day et al. in their study
using both in vitro osteoblastic culture and in an in vivo murine model, inhibition of Wnt
signaling results in a significant downregulation of osteoblasts, and subsequently, osteocytes.
Osteocytes produce receptor activator NF-κB ligand (RANKL) (Goldring, 2015).
Increased RANKL production by osteocytes leads to increased osteoclastogenesis, causing
increased bone resorption. Osteocytes produce osteoprotegerin (OPG), which together with
RANKL, mediates bone resorption by osteoclasts. However, OPG is anti-osteoclastogenic, it
binds RANKL and blocks it from binding receptor activator NF-κB. Osteocyte death stimulates
the differentiation of osteoclast differentiation (Yang et al., 2020). In summation, as the most
abundant bone cell type, osteocytes are a key component of bone homeostasis and remodeling.
mediate bone remodeling by cell-to-cell interactions with osteoblasts and osteoclasts, as well as
through signaling via ligands like RANKL, Wnt, and sclerostin.

Bone Structure Development

Mature osteoblasts and osteoclasts form impermanent material structures termed basic
multicellular units (BMUs). In a BMU, osteoclasts resorb bone in a tunneling pattern. The
osteoclast progenitors are activated and recruited to the surface of mineralized bone tissue in
response to signaling molecules from osteocytes and osteoblasts, as well endocrine signals such
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as parathyroid hormone and calcitonin in vivo (Kim et al., 2020)(Salhotra et al., 2020). When
serum calcium levels decrease, the decrease stimulates the parathyroid gland to release
parathyroid hormone. Parathyroid hormone acts directly on osteoblasts and indirectly increases
osteoclast differentiation and activity (Zhao et al., 1999). The opposing hormone to parathyroid
hormone is calcitonin, which is secreted by the thyroid in response to rising serum calcium
levels. Calcitonin inhibits osteoclastic resorption and indirectly increases osteoblastic bone
formation (Hsiao et al., 2020).
Parathyroid hormone acts directly on mesenchymal and stromal cells of the osteoblast
lineage. These cells then regulate the differentiation of osteoclast precursor cells through cell-tocell contact and osteoclast inducing ligands such as osteoclast differentiation factor (Zhao et al.,
1999). When the osteoclast precursors differentiate into mature osteoclasts, they resorb the bone,
releasing ions and degrading the bone structure. Mature osteoclasts release transforming growth
factor β (TGF- β) from the bone matrix, which, in addition to osteoclast to osteoblast coupling,
activates the osteoblasts (Udagawa et al., 2021). Osteoblasts follow the osteoclasts and deposit
unmineralized matrix, called osteoid, into the voids the osteoclasts leave behind in mineralized
bone matrix (Robling et al., 2006). The bone tissue serves as a metabolic reservoir for ions,
mainly calcium and phosphate, which are released into serum or supernatant during resorption
(Wawrzyniak and Balawender, 2022).

3D model

With the development of 3D models, major advancements have been made in research
and numerous applications for 3D models have been discovered (Fatehullah et al., 2016). Twodimensional (2D) cell culture has been the standard for in vitro research for decades. However,
5

three-dimensional (3D) cell culture and organoids offer mechanical and chemical biomimicry
closer to in vivo conditions. 3D cell culture is not without its challenges, as the methods for
developing 3D cultures are newer, the refinement of 3D models is an ongoing process (Duval et
al., 2017).
Between the physical limitations of 2D models, and the ethical and logistical demands of
animal models, 3D organoid models offer many advantages that bypass these limitations. 3D
organoid models more faithfully replicate conditions in vivo and reproduce unique organ
microenvironments. Cells in 3D models have been shown to mimic in vivo cell differentiation,
physiology, and signaling more accurately than 2D models. Hydrogels-based cultures provide a
double advantage in 3D culture because they are effective substitutes for the extracellular matrix
and they create spheroid structures (Jensen and Teng, 2020). Existing research has confirmed
that in vitro 3D bone tissue models exhibit expression of osteoblast and osteocyte markers
equivalent to in vivo bone tissue (Nasello et al., 2020). Further, 3D bone models better mimic the
in vivo microenvironments in which OBs and OCs reside than 2D models (Sun et al., 2015).
While several in vitro models of engineered bone cells have been successfully developed, there
is still a need for 3D models that accurately mimic all phases of bone homeostasis, and exhibit
resorption as well as bone formation (Remmers et al., 2020). While the hydrogel form and
plating method of this study relies on advancements made by Visconti et al. and their 3D model
using human-derived cell lines, this research focused on developing a similar murine model
because it is more cost-effective, and a wealth of molecular tools are available for this species.
This murine model was initially developed by Jaymes Fuller, the treatments are unique to this
study. Using the protocol developed by Jaymes Fuller, MC3T3-E1 cells and RAW264.7 cells
were used as viable cell types to grow physiologically comparable 3D bone organoids.
6

In summary, the purpose of this research was to cultivate a 3D bone model from murinederived cells that contained osteoblasts and osteoclasts which would engage in bone
homeostasis. After the bone tissue achieved homeostasis, insulin and magnesium were
administered so that any dose-dependent effects on bone metabolism could be observed. In our
3D model, we have observed high viability of OBs and OCs, which produced a 3D bone
organoid that supports bone formation and resorption under homeostatic conditions.
Insulin
Insulin is an anabolic peptide hormone that plays a critical role in regulating metabolism
and cell growth. Insulin receptors are present on the surface of almost all mammalian cells where
they activate complex signaling systems, including the PI3K and ERK cascades (De Meyts,
2015). Insulin has an important role in bone homeostasis because it influences osteoblast
proliferation and differentiation. In addition to directly stimulating the proliferation of osteoblast
in vitro, insulin has been shown to induce osteoblastic markers, namely alkaline phosphatase,
osteocalcin, and collagen type I (Akune et al., 2002). An in vivo study by Cornish et al. showed
that local administration of insulin can increase bone formation, the overall number of
osteoblasts and osteoblast surface area, as well as the osteoid surface area (Cornish et al., 1996).
At the same time, insulin also plays an important role in regulating chondrocyte proliferation and
differentiation (Pramojanee et al., 2014). A study by Kream et al. found that insulin at
concentrations ranging from 1nM to 1uM increased the amount of collagen synthesized in rat
calvaria organ cultures (Kream et al., 1985). Finally, in vitro studies have demonstrated that
insulin decreases the resorptive activity of osteoclasts. For example, Huang et al demonstrated
that insulin treatment decreased the number of TRAP+ osteoclasts and reduced osteoclast
differentiation using an ex vivo osteoblast cultures. (Huang et al., 2010)
7

Magnesium
Magnesium is one of the most abundant cations in the human body and the second most
abundant intracellular cation. It is a necessary cofactor for several hundred enzymes, and
important to many basic functions such as glycemic control, muscular contraction, and
neuromuscular conduction. Magnesium is a key ion for energy production, synthesizing
materials in the nucleus, active transmembrane ionic transport, and bone development. Bone
stores approximately 60% of the body’s total magnesium content and is important to regulating
overall magnesium homeostasis (Al Alawi et al., 2018). Magnesium promotes osteoblast
proliferation and differentiation and has been shown to increase the phosphorylation of ERK in
osteoblasts in vitro (Wang et al., 2018). In vivo studies have suggested that magnesium promotes
growth of new bone tissue and supports bone remodeling. In a study by Diaz-Tocados et al,
magnesium concentrations of 0.8mM, 1.2mM, and 1.8 mM were found to increase osteogenesis
ex vivo. Higher concentrations of magnesium in this study (1.2 and 1.8 mM) were found to
enhance proliferation of bone marrow mesenchymal stem cells and increase alkaline phosphatase
activity significantly. In addition, bone matrix mineralization, analyzed by Alizarin Red staining,
was found to be higher in cells cultures with 1.2mM and 1.8 mM magnesium chloride (DiazTocados et al., 2018). In a coculture of osteoclasts and osteoblasts by Wu et al., it was shown
that magnesium had dose-dependent effects on differentiation of both cell types. For example, at
1:1 and 1:2 dilutions of pure magnesium ingot, osteoclast precursors were less adherent than in
lower concentrations of magnesium. Magnesium increased protein production in the coculture at
low concentrations and increased protein production in higher concentrations. Moreover,
magnesium had a stronger effect on cells at time points of day 7 and 14 than it did at days 21 and
28. TRAP activity also showed time-dependent and dose-dependent effects in the presence of
magnesium, with reduction in TRAP (corresponding with a reduction in osteoclast activity)
8

correlating to increasing higher concentrations of magnesium. RANKL increased in the higher
concentrations of magnesium over the 28-day time course. Osteoblast mineralization function
was assessed by Alizarin Red staining, and it was found that in the coculture that received 1:1
magnesium treatment, there was significantly increased mineralization compared to other
concentrations (control, 1:5 and 1:10 concentrations) (Wu et al., 2015). Data has also shown that
magnesium deficiency results in an increase of skeletal fragility and bone resorption, and a
decrease in bone formation. But other studies performed on osteoclast precursors in vitro have
found that severe magnesium deficiency, while increasing osteoclastogenesis, decreases the rate
of resorption. In the study by Belucci et al, osteoclast precursors were induced into
osteoclastogenesis by supplementing media with M-CSF and RANKL and with 4 concentrations
of magnesium--0.8mM, 0.4mM, 0.08 mM, and 0mM—to compare changes in osteoclastogenesis
and activity. The cultures were analyzed using DNA quantification, measuring release of
adenylate kinase to determine cytotoxicity, and TRAP staining. Cell viability assays found that
magnesium deficiency or increased supplementation had no effect on cell viability. DNA
quantification confirmed that there was no difference in DNA amount linked to magnesium
concentration. The highest number of TRAP+ osteoclasts occurred at 0.08mM magnesium and
the lowest at 0.8mM. However, at the lower concentration (0.08mM), TRAP+ cells exhibited
decreased resorptive activity, suggesting that magnesium deficiency increased osteoclast
formation but decreased resorption. This is most likely due to insufficient energy metabolism
directly caused by lack of magnesium for magnesium-dependent enzymes. In vivo and in vitro
studies have demonstrated that magnesium deficiency results in a higher number of osteoclasts,
but a lower ratio of functional osteoclasts (Belucci et al., 2013). In terms of skeletal fragility
associated with magnesium deficiency, the same insufficient energy metabolism extends to
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osteoblastogenesis (Song, Xu, et al). Magnesium is a cofactor for enzymes that regulate calcium
release from bone matrix, and in magnesium deficiency, there is increased calcium release from
bone as well as decreased osteoblast activity, which could cause skeletal fragility even when
resorption-capable osteoclasts have decreased (Song et al., 2022). In a human study by Orchard
et al, it was found that decreased magnesium intake correlated to lower bone mineral density, but
that the decreased density did not translate into an increased risk of fractures (Orchard et al.,
2014). Other human studies have shown that magnesium supplementation improved bone
mineral density and reduce the expression of resorption markers (Aydin et al., 2010). Since
magnesium impacts bone homeostasis in multiple ways, further study is needed to uncover the
exact mechanisms that cause fragility in magnesium deficiency (Song et al., 2022)(Orchard et al.
2014).

10

Figure 1: Bone cell lineages and differentiation. Bone tissue comprises several cell types.
Osteoprogenitor cells become osteoblasts, which carry out ossification. As osteoblasts deposit bone
matrix, mature osteoblasts trapped in the matrix become osteocytes. Osteocytes regulate bone
homeostasis. Hematopoietic stem cells differentiate to osteoclast precursors. Osteoclasts resorb bone.
Figure by K. Lefferts. Created with biorender.com.
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Materials and Methods
Cell Culture Preparation of MC3T3-E1 Osteoblast Cells
MC3T3-E1 cells (atcc.org CRL-2593™) were plated and maintained in sterile conditions in
sterile conditions. Cells were cultured in Minimum Essential Medium, Alpha 1X (Corning, Inc.,
cat# 10-022-CVR) supplemented with 10% fetal bovine serum (FBS) (R&D Systems, cat#
S11150) and 1% 100x penicillin/streptomycin (Corning, Inc., cat # 30-002-CI). The plates were
maintained at 37°C in a 5% CO2 incubator prior to the start of the experiment.
Cell Culture Preparation of RAW 264.7 Cells
RAW 264.6 cells (atcc.org TIB-71™) were plated and maintained in sterile conditions in sterile
conditions. Cells were cultured in Minimum Essential Medium, Alpha 1X (Corning, cat# 10022-CVR) supplemented with 10% FBS and 1% penicillin/streptomycin (Corning, cat#30-002CI). The plates were maintained at 37°C in a 5% CO2 incubator until their use in cell
proliferation assay and day 28 of osteoblast differentiation and mineralization in the 3D model.
Cellular Proliferation
Cellular proliferation was assessed by MTT assay. MC3T3-E1 cells were seeded in a 96-well
plate at a density of 20,000 cells per well, cultured in Minimum Essential Medium, Alpha 1X
(Corning cat# 10-022-CVR) supplemented with 10% FBS and 1% P/S, and allowed to adhere for
24 hours at 37°C in a 5% CO2 incubator. After the 24-hour incubation, the media were replaced
with 12 treatment groups: 6 dosing points of insulin and 6 dosing points of magnesium chloride
(MgCl2). Insulin = 0nm, 50nm, 125nm, 250nm, 500nm, 1000nm. Magnesium Chloride = 0mM,
0.08mM, 0.12mM, 0.53mM, 1.2mM, 1.8mM. The cells were incubated for 24 hours at 37°C in a
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5% CO2 incubator. Then, 10μL of MTT solution (5mg/mL in 1X Phosphate Buffered Saline
(PBS)) was added to each well. The plates were incubated for 4 hours at 37°C. The media was
removed from each well and 100μL of dimethyl sulfoxide (DMSO) was added to each well. The
plates were incubated at 37°C for 15 minutes. The absorbance of the resulting formazan crystals
was measured at a wavelength of 570nm using a Varioskan™ LUX microplate reader (Thermo
Scientific™).

3D in vitro model
MC3T3-E1 cells were seeded at a density of 60,000 cells per 17µL of cold Matrigel® Matrix
Phenol Red-free (Corning Inc, cat #356237). The suspension of cells was kept on ice until it was
pipetted as 17 µL droplets in the wells of a 96-well plate (Corning #353916). The plate was
incubated at 37°C for 7 minutes to solidify the gel. The, 200µL of osteoblast differentiation
media was added to each well. Osteoblast differentiation media was Minimum Essential
Medium, Alpha 1X supplemented with 10% FBS and 1% 100x penicillin/streptomycin with the
additional supplements of bone morphogenic protein 2 (BMP-2), L-ascorbic acid (L-aa),
dexamethasone, and beta glycerol phosphate (BGP). Plates were incubated and cultured at
37°C/5% CO2 for 28 days. 50% of the OB differentiation media was replaced with OB
differentiation media every two to three days.
On Day 28, RAW264.7 cells were suspended in a 1:1 combination of osteoblast differentiation
media and osteoclast media. Osteoclast media was Minimum Essential Medium, Alpha 1X
supplemented with 10% FBS and 1% 100x penicillin/streptomycin with the additional
supplements of Macrophage Colony Stimulating Factor (M-CSF) and receptor activator of
13

nuclear factor kappa-B ligand (RANKL). The cells were seeded at a density of 60,000 cells per
well in 100µL media. Plates were incubated and cultured at 37°C/5% CO2 for fourteen days.
50% of the media was replaced with 1:1 OB/OC differentiation media every two to three days.
Treatments
On day 42, once sufficient bone homeostasis was reached, treatments were introduced to the 3D
model to study the dose-dependent effects of insulin and magnesium on the bone-like fragments.
Insulin was added to two groups, low insulin dose group received 50nM insulin per well. High
insulin dose group received 125nM per well. The insulin was suspended in the osteogenic media.
Magnesium chloride (MgCl2) was used at low (0.53 mM), medium (1.2 mM), or high (1.8 mM)
suspended in osteogenic media. The osteogenic media control group received osteogenic media
without additional treatments. Serum-free media was used as a negative control.

Characterization of 3D in vitro models
Calcium Deposition
On day 7 and 21, the bone organoids were stained to assess calcium deposition. The spent media
were removed from each removed from each well, the wells were washed twice with 200µL of
1X PBS. 200µL of 4% formaldehyde was added to each well and the plates were incubated at
room temperature for thirty minutes to fix the samples. The formaldehyde was removed and the
wells were washed three times with deionized water. 100µL of 1X 40 mM Alizarin Red staining
reagent (Millipore Sigma, cat# TMS-008-C) was added to each well and the plates were shaken
gently for thirty minutes at room temperature. The Alizarin red staining reagent was removed
and the plates were washed three times with deionized water. The plates were immediately
14

analyzed through light microscopy (Nikon Eclipse Ti) and the images were captured. The plates
were left at an angle for 2 minutes to facilitate the removal of excess deionized water, which was
aspirated. 200µL of 10% (v/v) acetic acid was added to each well and the plate was shaken and
incubated at room temperature for thirty minutes. Then the bone-like fragments were scraped
from the plate and transferred with 10% (v/v) acetic acid to microcentrifuge tubes. The tubes
were vortexed for 30 seconds, then heated for 10 minutes at 85°C. The tubes were placed on ice
for five minutes immediately after heating, then centrifuged for fifteen minutes at 20,000g. The
supernatant was transferred to a new tube and 200 µL of 10% (v/v) ammonium hydroxide was
added. Aliquots of 150µL of the supernatant were transferred to a 96-well plate and read at 405
nm using a Varioskan™ LUX microplate reader (Thermo Scientific™).
Alkaline Phosphatase Activity
On days 7, 14, and 21, spent medium from the 3D cultures was collected and analyzed for
alkaline phosphatase activity. Standards for the ALP assay were prepared according to Alkaline
Phosphatase kit protocol (abcam, cat # ab83369). Samples were diluted 1:1 with ALP assay
buffer at a volume of 40 µL of sample and 40 µL of assay buffer. The diluted samples were
loaded into a 96-well plate with 50 µL of pNPP solution and the plate was covered from light
and incubated at room temperature for sixty minutes. After sixty minutes, 20µL of Stop solution
was added to each well, the plate was shaken for three minutes, and the absorbance was read at
405 nm using a Varioskan™ LUX microplate reader (Thermo Scientific™).
Protein Concentration
On days 7 and 14, medium from the 3D cultures was collected and analyzed to determine total
protein concentrations by bicinchoninic acid (BCA) assay (Thermo Scientific™ cat# 23225).

15

The assay was run on spent media from the samples. The working reagent was prepared
according to the manufacturer’s instructions. Standards for the BCA assay were prepared
according to kit instructions. 25 µL of sample was added to wells on a flat-bottom 96-well plate.
200 µL of working reagent was added to each well, and the plate was shaken for 30 minutes to
mix reagent and sample. The plate was covered and incubated at 37C for 30 minutes. The plate
was allowed to cool to room temperature and was promptly read at 532 nm using a Varioskan™
LUX microplate reader (Thermo Scientific™)
Type I Collagen C-telopeptide (CTX-1) Peptides
On days 7 and 14, medium from the 3D cultures was collected and analyzed for type 1 collagen
C-telopeptide (CTX-1) by ELISA assay (Chondrex, Inc., Woodville, WA; cat# 6033). The assay
was run on spent media from the samples. The plate was prepared according to the
manufacturer’s instructions. The capture antibody was added and incubated at 4°C overnight.
75µL of each sample or standard was added to 75µL of biotinylated CTX-1. 100µL of this
mixture was added to each capture antibody-coated well. The plate was incubated at room
temperature for two hours. The plates were washed three times with 1X wash buffer. 100µL of
streptavidin peroxidase was added to each well, and the plate was incubated for thirty minutes.
The plate was washed three times with 1X wash buffer. 100µL of 3,3’, 5,5’-tetramethylbenzidine
(TMB) peroxidase solution was added to each well, and the plate was incubated for 25 minutes.
50µL of sulfuric acid stop solution was added to each well. The absorbance was read at 450nm
using a Varioskan™ LUX microplate reader (ThermoFisher Scientific™).
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Protein Isolation
On day 7, the bone organoid model (BOM) samples were harvested from each treatment group
using M-PER™ Mammalian Protein Extraction Reagent (Thermo Fisher Scientific, cat # 78501).
The 96-well plates were placed on ice to liquify the Matrigel™ matrix and the media and
liquified matrix were aspirated. The BOMs were washed in PBS. Then, 100 µL of M-PER™ was
added to each well and the plates were shaken gently for five minutes. The lysate was transferred
to microcentrifuge tubes and centrifuged at 14,000 g for 8 minutes. The supernatant was
transferred to new tubes for analysis.
Immunoblotting
Protein expression of COX-2 was determined via immunoblotting. On day 7, the bone organoids
were harvested for protein isolation, as described previously. The lysate was used for
immunoblotting. Samples were prepared for separation by adding 3.75µL of NuPAGE LDS
Sample Buffer (4X) (ThermoFisher Scientific, NP0008) and 1.5µL mercaptoethanol to 9.75 µL
of sample. The samples were heated at 70°C for 10 minutes, then separated using NuPAGE BisTris Mini protein gels (ThermoFisher Scientific, cat# NP0329BOX) per manufacturer protocol.
The gel was transferred to a polyvinylidene difluoride (PVDF) membrane. Primary
immunodetection of GAPDH (R&D systems, cat# MAB5718) and COX-2 (Cell Signaling, cat#
4842S) was performed using rabbit- and mouse-derived antibodies. Secondary immunodetection
was performed with anti-rabbit IgG (R&D systems, cat#HAF008) and anti-mouse IgG (R&D
systems, cat# BAF018) HRP-conjugated antibodies. Results were detected by
chemiluminescence via a Protein Simple Fluorchem E machine (Protein Simple).
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Statistical Analyses
Data was processed in SkanIt RE 6.1 for microplate readers, exported to Excel and transferred to
SigmaPlot software (SyStat Software, San Jose, California) for analysis. One-way ANOVA was
used to detect significant treatment effect, as well as appropriate t-tests and post-hoc tests. P
values < 0.05 were considered significant.

Figure 2: Schematic, timeline, and morphological development of 3D bone model. In vitro threedimensional bone model was developed by differentiation of precursor cells using osteogenic media.
Osteoblast precursors were embedded in a Matrigel™ matrix, osteoclast precursors were added to
model after sufficient mineralization of the matrix. After the 3D model reached homeostasis, treatments
were added. Figure by K. Lefferts. Created with biorender.com.
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Results
I. In a single-cell monolayer in vitro, insulin and magnesium chloride produced dosedependent effects on cell viability.
The effect of varying concentrations of magnesium chloride and insulin on cell viability
was observed by MTT assay. Cell proliferation was analyzed in RAW 264.7 and MC3T3-E1
cells. Cells were treated with supplemented media and 0mM, 0.08mM, 0.12mM, 0.53mM,
1.2mM, 1.8 mM MgCl2 or 0.0nM, 50nM, 125nM, 250nM ,500nM , 1000nM INS. The MTT
assay was performed after a 24hr treatment period (Figure 1).
MgCl2 treatment of 0.08mM and 0.12mM had a significant negative effect on MCT3T3E1 proliferation compared to the control concentration, 0.0mM MgCl2 (P<0.001 and P=0.027,
respectively). A 0.08mM resulted in a 1.37-fold decrease while 1.2mM resulted in a 2.3-fold
decrease compared to 0.0mM., however these changes were not considered statistically
significant. The 1.2mM MgCl2 also significantly reduced cell viability compared to 0.12mM,
0.53mM, and 1.8mM (P<0.050).
In RAW 264.7 cells, 1.2mM MgCl2 elicited a significant decrease of 1.8-fold or higher
(P<0.050) in cell viability compared to all other treatment concentrations and control.
Statistically significant dose-dependent effects of insulin on MCT3T3-E1 cells were not
observed. 125nM INS had a negative effect on cell proliferation when compared to 0mM (2.18fold increase, P<0.001), 50mM (2.27-fold decrease, P<0.001), 500mM (two-fold decrease,
P<0.001), 1000mM (2.1-fold decrease, P<0.001). INS significantly decreased cell proliferation
at 250nM compared to 0mM (1.46-fold decrease, P<0.016), 50mM (1.51-fold decrease,
P<0.007), and 1000mM (1.4-fold decrease, P=0.034).
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Figure 3: In a single-cell monolayer in vitro, insulin and magnesium chloride produced dose-dependent
effects on cell viability. (A) RAW 264.7 cells treated with MgCl2. (B) MC3T3.E1 cells treated with MgCl2
(C) RAW 264.7 cells treated with insulin (D) MC3T3.E1 cells treated with insulin. Treatment groups
included 50nM, 125nM, 250nM, 500nM, 1000nM of insulin (INS) and 0.08mM, 0.12mM, 0.53mM,
1.2mM, 1.8 mM of magnesium chloride. Cells were cultured for 24 hours before treatment, cells were
exposed to treatment for 24 hours. Viability was assessed by MTT assay. Error bars represent mean ±
SD. */^ signify statistically significant difference between groups, corresponding p values are stated.
n=6.
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II. Calcium Deposition in the 3D model showed some dose dependent differences and an
increase in calcium deposition over time.

Untreated

OSM

MgCl2

INS

Low

High
Figure 4: Calcium deposition in 3D models after 21 days of treatment. Black arrows
indicate areas of denser calcium deposition. Figure by K. Lefferts.
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Based on the results of the MTT assay, two concentrations were chosen to study the
effects of insulin on the 3D model, a low dose of 50nM and a high dose of 125nM. Three
concentrations of magnesium were selected, low (0.53mM), medium (1.2mM), and high
(1.8mM).
At day 7 of treatment low insulin and all doses of magnesium (low, medium, and high)
showed significant decrease in calcium deposition compared to the untreated group (Figure 5,
P<0.050). Compared to OSM, all concentrations of magnesium (low, medium, high) showed
significantly lower absorbance values, proportional to calcium deposition (Low, P=0.005;
Medium, P= 0.006; High, P=0.011). Low insulin was statistically different compared to OSM,
P=0.048.
At day 21, all treatments groups showed a significant increase in absorption compared to
the untreated group. OSM group showed increased absorbance by 1.81-fold (P<0.001). Low,
Medium, and High MgCl2 showed a >1.66-fold increase (P<0.001, P<0.001, P<0.050,
respectively) when compared to untreated. Low and high insulin group had a >1.50-fold
increase a statistically significant increase compared to the untreated group (P<0.050). While the
untreated group significantly decreased absorbance over time, all other treatment groups
increased concentration of calcium deposition over time (increase at day 21 compared to day 7,
Figure 5).
There was no significant change in calcium deposition over time in the untreated group.
In the OSM-treated group, calcium deposition increased 1.6-fold between day 7 and day 21
(P<0.050, Figure 5). Calcium deposition significantly increased in insulin-treated samples over
time. In low insulin treated samples, there was a 2.04-fold increase in calcium deposition from
day 7 to day 21 (P<0.001, Figure 5). In high insulin samples, there was a 1.67-fold increase in
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calcium deposition over the same time interval (P=0.007). In the low, medium, and high
magnesium group, calcium deposition increased 3.88-fold, 3.46-fold, and 2.34-fold from day 7 to
day 21 (P<0.001, P<0.001, P=0.004), respectively.

Figure 5: Calcium deposition by treatment shows some dose-dependent effects in 3D bone model,
calcium deposition increases over time. Influence of insulin and magnesium treatments on calcium
deposition were assessed by alizarin red staining. Changes by treatment concentration and over time
between days 7 and 21 of treatment were assessed. Treatment groups include untreated medium,
osteogenic medium (OSM), low INS (50nM), high INS (125nM), low MgCl2 (0.53mM), medium MgCl2
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(1.2mM), and high MgCl2 (1.8mM). Significant differences between treatment groups are noted
(P<0.050, one-way ANOVA). . Error bars represent mean ± SD. Symbols #,^,*,@, + signify statistically
significant difference between groups, corresponding p values are stated. n=3.

III. Alkaline Phosphatase activity does not show dose-dependent differences in MgCl2
treated samples, Insulin-treated samples show dose-dependent shift in alkaline phosphatase
activity.
Spent media was collected at days 7, 14, and 21 so that alkaline phosphatase activity
could be analyzed. Across all three timepoints, the alkaline phosphatase activity in the untreated
group was significantly lower compared to all other treatment groups (P<0.001). At day 21, there
was a significant decrease in alkaline phosphatase activity as insulin concentration increased,
resulting in a 1.40-fold decrease at high insulin concentration compared to low insulin
concentration (P<0.050, Tukey test).
There was a consistent and significant decrease in alkaline phosphatase activity in the
high magnesium group over time. From day 7 to day 14, alkaline phosphatase activity decreased
by 1.10-fold (P=0.008, P<0.050, respectively). From day 7 to day 21, there was a 1.12-fold
decrease in alkaline phosphatase activity (P=0.007 and P<0.050, respectively). There was a
consistent decrease in alkaline phosphatase in the high insulin group, alkaline phosphatase
decreased 1.45-fold from day 7 to day 14, 1.20-fold from day 14 to day 21, and 1.75-fold from
day 7 to day 21(P=0.037).
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Figure 6: Alkaline phosphatase (ALP) activity shows some dose-dependent effects in insulin-treated 3D
bone model. ALP activity was assessed by measuring the conversion of p-nitrophenyl phosphate (pNPP)
to p-nitrophenol (pNP) using supernatant samples from days 7, 14, and 21. Significant differences
between treatment groups are noted (P<0.050, one-way ANOVA). Error bars represent mean ± SD.
Symbols */+ signify statistically significant difference between groups, corresponding p values are
stated. n=3.

IV. Bone resorption levels measured by CTX-1 activity did not significantly change
between time course or treatment dose.
Bicinchoninic acid (BCA) assay was performed to determine the protein concentration in
the bone organoid supernatant. Then, using enzyme-linked immunosorbent assay (ELISA),
culture supernatant was analyzed to investigate if magnesium chloride or insulin altered the
expression of CTX-1. The CTX-1 ELISA was performed on day 7 and 14 samples. The results
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were quantified, and protein concentrations were normalized using data from BCA assay. The
ELISA did not detect significant differences in CTX-1 expression based on dose or time.

Figure 7: Bone resorption biomarker C-telopeptide of type I collagen (CTX-1) expression does not
exhibit dose-dependent effects. Media from the bone organoid model was collected at days 7 and 14
and assayed by ELISA for CTX-1 expression. n=3.

VI. The inflammatory COX-2 pathway is not detectably activated by insulin or magnesium
chloride in the 3D model
To investigate if magnesium chloride or insulin altered the activation of the COX-2
pathway, a Western blot was performed on day 7 isolated protein samples. The Western blot did
not detect COX-2 expression in any samples.
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Figure 8: Western Blot analyzing COX-2 expression. Samples from day 7 of treatment were analyzed by
Western blot. Western blot shows COX-2 and GAPDH protein band expression for untreated group,
osteogenic medium group, and each INS and MgCl2 treatment group. Samples from VSO4-treated
MC3T3-E1, known to produce COX-2 expression were used as a control.

There was no detectable COX-2 expression in all treatment groups. Vanadium sulfate- (VSO4)
treated MC3T3-E1 samples from a previous experiment were used as a control, as COX-2
expression had been confirmed in these samples previously (VSO4-treated samples courtesy of
Bryan Sosa, Cottrell Research Group).
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Discussion
In the present study, the effects of magnesium chloride and insulin treatment on bone
homeostasis in a 3D bone model were investigated. Our data found that insulin-treatment groups
displayed lower calcium deposition than osteogenic supporting media. Interestingly though
calcium deposition increased over time in the insulin-treated groups, indicating a positive
association between continued insulin treatment and ossification. In some studies, insulin and
insulin mimetics have been shown to enhance osteoblastogenesis and indirectly reduce osteoclast
proliferation. This is supported by studies by Clemens and Karsenty which deleted the insulin
receptor in osteoblasts in an in vivo murine study and found a decrease in osteoblastogenesis.
Their studies further found that insulin signaling that affected osteoblasts was also part of a
feedforward loop, as the insulin signaling increased osteoprotegerin expression by the
osteoblasts, which interfered with RANKL binding by osteoclasts, thereby decreasing osteoclast
proliferation (Clemens and Karsenty, 2010). Abnormally elevated levels of insulin have been
shown to increase bone mass through modulation in bone homeostasis, according to data
compiled by Comptson from several in vivo human studies, this includes increased BMD and
increased bone strength in trabecular and cortical bone (Comptson, 2018). Other studies have
demonstrated a positive association between bone mass and insulin levels in vivo (CampilloSanchez et al., 2020). For example, a study of hyperinsulinemia and insulin resistance in
nondiabetic, postmenopausal women by Shanbogue et al. found that, in vivo, with higher levels
of insulin resistance, and therefore higher levels of circulating insulin, had increased bone
mineral density (BMD) compared to women with lower levels of endogenous insulin
(Shanbogue et al., 2016). However, other studies have shown a negative association or no
association between bone mineral density, such as a study in men by Abrahamsen et al. that
found no correlation between BMD and insulin, determined by bone measurement by a
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densitometer (Abrahamsen et al., 2000) (Campillo-Sanchez et al., 2020). In this study, we
quantified bone homeostasis by measuring osteoblast and osteoclast activity by quantifying ALP
and CTX-1 to measure osteoblast and osteoclast activity, respectively.
Our data shows that insulin decreases ALP activity as insulin concentration increases,
that is, at 125nM there was an increase compared to 50nM of insulin. Further, ALP activity
increased as time increased in the insulin-treated samples, at the 21-day timepoint (compared to
day 14 ALP activity). Some data has shown that insulin signaling promotes ossification and
stimulates the release of osteocalcin from OBs in a murine model animal study (Ivaska et al.,
2015). Similarly, an in vitro study using murine osteoblasts found that insulin supported
osteoblast differentiation and promoted osteocalcin expression (Zhang et al., 2012). However,
Sherk et al. found that induced hyperinsulinemia in humans did not significantly alter the
expression of ALP from the baseline levels, however it did significantly increase osteocalcin
levels (Sherk et al., 2020). Treatment with insulin in our 3D-model did follow these patterns, in
fact, it appeared to reduced ALP activity. It is possible that the presence of osteoclasts may have
affected ALP activity by secreting mediators that affect osteoblast function.
During bone resorption, type I collagen undergoes enzymatic degradation. Fragments
released from the degradation include C-telopeptide of type I collagen (CTX-1) which can be
used as an indicator of osteoclast activity. The present study demonstrated that CTX-1 activity
did not significantly change between time course or treatment dose. This is counter to CTX-1
activity results from an in vivo human study by Ivaska et al. Ivaska et al. induced
hyperinsulinemia in women after an overnight fast by using hyperinsulinemic clamps at doses of
5mmol/L for 4 hours at a rate of 40mU/m2 per minute (low insulin group) or 5mmol/L for 4
hours at a rate of 72mU/m2 per minute (high insulin group). After four hours of insulin exposure,
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blood samples were drawn and analyzed for CTX-1, TRAP levels were also assessed. Ivaska et
al. indicated that insulin suppressed bone resorption and decreased CTX-1 expression in a dosedependent manner, with a small, significant decrease in CTX-1 in the low dose group and a more
pronounced decrease in CTX-1 in the high insulin group. Ivaska et al. also found time-dependent
effects, both 4-hour groups had altered CTX-1 levels, whereas a 2-hour exposure did not alter
CTX-1 levels compared to no insulin (Ivaska et al., 2015). However, a coculture of osteoblastic
SaOS-2 cells and THP-1-derived osteoclasts, Häussling et al. found that NTX levels, which is a
similar marker of collagen degradation and osteoclast activity to CTX-1, were not significantly
affected by doses of insulin (high insulin in this study was 160 I.U./l insulin) in a 3D culture
even though the same dose decreased collagen degradation in their comparative 2D coculture.
Häussling et al.’s high insulin level, 160 I.U./l is equivalent to 111.2nM, remarkably higher than
the 125nM used as the high insulin concentration for our study. (Häussling et al., 2021). This
data suggests that the 2D cultures and monocultures may not accurately predict insulin’s effect
on a 3D cultures environment. Interestingly, Sherk et al. also found that serum CTX-1 levels did
not significantly decrease during induced hyperinsulinemia in diabetic patients (Sherk et al.,
2020). Therefore, further investigation is needed to establish a clear link between the CTX-1
activity observed in 3D bone models with in vivo models.
The regulation of insulin may be important to better understand the above inconsistencies
relating to its effect on bone homeostasis. Insulin activates the insulin signaling pathway and
activates extracellular signal-regulated kinase (ERK 1/2) (Campillo-Sanchez et al.,
2020)(Tripolino et al., 2021). Insulin stimulates two metabolic pathways in pre-osteoblasts and
osteoblasts: the mitogen-activated protein kinase (MAPK) pathway and the phosphatidylinositol
3-kinase (PI3-K/AKT) pathway (Tripolino et al., 2021). These pathways support the growth,
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proliferation, and survival of OB cells. Although insulin has an anabolic effect on bone mass,
when OB cells are activated, they stimulate the release of receptor activator of NF-kB ligand
(RANKL), which binds to osteoclast receptor activated of NF-kB (RANK) receptors. The
binding of RANKL to RANK receptors stimulates OC proliferation and maturation, leading to
resorption. Therefore, insulin plays a key role in bone metabolism, as it regulates both bone
deposition and resorption (Campillo-Sanchez et al., 2020). In future studies using this model,
RANKL levels can be analyzed to assess osteoclastogenesis in conjunction with methods such as
CTX-1 ELISA, a marker for active osteoclasts, used in the present study. Osteoclastogenesis is
also regulated by osteoprotegerin (OPG), which is a decoy RANKL receptor. OPG is expressed
by OBs and inhibits osteoclastogenesis (Kamiya et al., 2008). Häussling et al. demonstrated that
OPG strongly increased in the presence of high insulin in a 3D coculture. (Häussling et al.,
2021). In future studies, OPG levels can be analyzed as a negative regulator of OC development
and resorption. Some studies have found elevated levels of OPG positively correlate to
hyperinsulinemia in vivo, whereas other studies have found no positive correlation (Stanik et al.,
2018). The ratio of RANKL to OPG can be used to assess the overall balance of bone
homeostasis, making it an effective method in future research of this model. The RANKL/OPG
ratio adds additional insight into OB activity and OB-induced osteoclastogenesis, especially
when used in conjunction with ALP (osteoblast activity) and CTX-1 levels (osteoclast activity)
(Grimaud et al., 2003). Together, this information will help better understand the effect insulin
exerts on maintaining bone mass.
Bone mass is regulated by BMP and Wnt signaling. Research has indicated that Bmpr1a
deficiency in OB cells upregulates Wnt signaling (Kamiya et al., 2008). Insulin resistance has
been directly linked to losses in bone mineral density (BMD). Advanced glycosylation products
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(AGEs) have been proposed to reduce bone insulin resistance and fragility. AGEs act on both
OBs and OCs. AGEs suppress OB proliferation and differentiation. Further, AGEs activate the
NF-kB pathway in OB cells, which leads to inflammatory cytokines being released from OB
cells. These cytokines act on OC cells, stimulating proliferation and increasing resorption
(Campillo-Sanchez et al., 2020). Research conducted to better understand the exact relationship
between insulin levels, bone metabolism, AGEs, and other Wnt pathways would be helpful in
future studies.
Magnesium Chloride
Magnesium chloride treatments increased calcium deposition over time which may indicate a
positive role in osteoblastogenesis. It is pertinent to note that the effects of Mg2+ from other
studies, in conjunction with the results of MgCl2 treatment in monocultures in this study
determined the concentrations of MgCl2 used, however, osteoblasts and osteoclasts respond
differently to MgCl2 in coculture than in monoculture. In a study focusing on the effects of Mg2+
on a coculture of OBs and OCs, it was observed that higher concentrations of Mg2+, in the form
of Mg cuboid specimens cut from a 99.98 wt% Mg ingot, caused a significant increase in
RANKL production compared to lower concentrations. Further, in their study Mg2+ was found to
generate multinucleated osteoblast from monocytes in the coculture without the addition of
external RANKL or M-CSF. While an osteoclast monoculture was not able to endure high Mg2+
concentrations, research by Wu et al. clearly demonstrated increased tolerance to Mg2+ and a
reduction in concentration-dependent responses when osteoclasts and osteoblasts are cocultured.
Their study also demonstrated that osteoblasts recover more quickly from high doses of Mg2+
than osteoclasts (Wu et al., 2015). In the current study, alizarin red staining indicated decreased
calcium deposition across all MgCl2 concentrations compared to osteogenic supported media32

treated bone at Day 7. At day 21, calcium deposition increased significantly in all MgCl2
treatments and was comparable to the OSM control. Similarly, our data demonstrated the
alkaline phosphatase activity did not show dose-dependent differences in MgCl2-treated samples.
Overall, this study showed that MgCl2 did not significantly impact bone homeostasis.
In an in vitro study by Kong et al. using human dental pulp stem cells (DPSC), they
concluded that magnesium-enriched cultures displayed increased differentiation as a result of
Mg2+ activating ERK 1/2 and BMP2 signaling. Kong et al.’s study used Mg2+ in the form of
MgCl2, as did our study, however their doses for MgCl2 were 1, 5, and 10mM, providing insight
into the effects of MgCl2 at higher doses than our study. Kong et al. found that high MgCl2 did
not significantly affect proliferation of the DPSCs but did affect differentiation. They found that
Runx2 increased significantly at 1mM compared to 0mM MgCl2, and at 5mM and 10 mM
compared to 0mM and 1mM. Additionally, they found that mineralization significantly increased
at 5mM and 10mM MgCl2 compared to 0mM and 1mM (Kong et al.). Overall, MAPK signaling
activation increased at all doses of MgCl2, as did ERK phosphorylation. Levels of BMP2 also
consistently increased in a dose-dependent manner in response to MgCl2. Based on their results,
and the notable increases in differentiation and mineralization at 5mM and 10mM MgCl2, in
future studies higher doses of MgCl2 could be used in the 3D model to explore cell
differentiation and changes in ERK and BMP2 signaling. Further the combined effects of INS
and MgCl2 in a bone 3D model should be explored, as there is currently a lack of knowledge on
the effects of the two treatments together on bone homeostasis.
Exposure to factors such as insulin and MgCl2 at different levels can sometimes promote
inflammation. As a result, we measured the expression of COX-2, an inducible enzyme linked to
inflammation (Forwood, 1996). The results of this research indicate that MgCl2 and insulin did
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not stimulate COX-2 expression in a 3D bone model. Sandberg and Jansson studied the dynamic
between COX-2 and insulin in vitro, through cultured pancreatic islets isolated from rats, and in
vivo using a rat model. They found that in vitro effects were not as remarkable as in vivo effects.
However, their research focused on the effects of COX-2 on insulin, the effects of insulin on
COX-2 are less well studied. Sandberg and Jansson found that COX-2 increased insulin secretion
(Sandberg and Jansson, 2014). Coon et al. studied the effects of COX-2 on bone homeostasis in
vitro, using OB and OC cultures from COX-2 knockout and WT murine models. They concluded
that a lack of COX-2 expression resulted in decreased bone resorption. Furthermore, Coon et al
found that COX-2-mediated osteoclastogenesis regulates inflammatory bone resorption in both
WT and COX-2 knockout models, but osteoclastogenesis was significantly reduced in the COX2 knockout cultures compared to WT-derived cultures while RANKL and OPG expression were
also significantly reduced in the COX-2 knockout cultures (Coon et al., 2007).
Limitations/Future Directions
It is noteworthy that in vivo bone formation is not just a chemical process, it is also a
mechanical process. All cell culture models lack the mechanical loading that triggers
mechanostat activity in osteocytes, a critical aspect of bone formation in vivo. When osteocytes
act as mechanostats, they release insulin-like growth factor (IGF-I) in response to mechanical
overload (Ono et al., 2019). The IGF-I acts on OB cells to increase bone deposition and blocks
sclerostin, which is a Wnt pathway inhibitor (Crane et al., 2013)(Wędrychowicz et al.,
2019)(Garcia-Martin et al., 2019). IGF-I, like insulin, also bonds to insulin receptors (Belfiore et
al., 2009) Kamiya et al. found that downregulation of Wnt pathway signaling has been related to
decreased bone mass. In addition, OB-linked Wnt signaling was upregulated by suppressing
sclerostin, which causes Bmpr1 deficiency (Kamiya et al., 2008). When OB and osteocyte
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populations are unnaturally high, the mechanical stress signals are insufficient to activate Wnt
signaling (Ono et al., 2019). Therefore, a limitation of all in vitro studies, including the present
study, is the lack of mechanical stimulation of osteocytes to mimic in vivo conditions, which
may affect IGF-I release, sclerostin inhibition and downstream Wnt signaling.
OBs are comparatively short-lived and a constant supply of fresh OB cells is required to
maintain bone composition (Ono et al., 2019). In this model, it is still unclear if OB cells were
continuously formed past the initial seeding and differentiation of the MC3T3.E1 cells. In vivo,
bone marrow stromal cells would differentiate into OBs during homeostasis. However, without
the presence of bone marrow stromal cells, the supply of new cells to differentiate into OBs is
limited in the model. In future research, an investigation into the effects of multiple seeding of
OB precursor cells into the model should be studied. In this model, a biopolymer hydrogel was
used to encapsulate the osteoblast progenitors. The hydrogel provided a similar water content to
in vivo tissue and mimicked the extracellular matrix. However, it is possible that the mesh of the
hydrogel did not fully support matrix production or the mobility and proliferation of the cells
(Duval et al., 2017). In 3D models, proliferation rates are slower and more in line with in vivo
cell proliferation than 2D models (Jensen and Teng, 2020) (Langhans, 2018). Further studies
could be completed to better understand OB proliferation rates and relate this information to
bone homeostasis in the 3D Model.
It is important to continue to reevaluate experimental results established in previous
research, as well as to uncover the differences between research previously conducted in 2D
models and in vivo. Most of the existing knowledge regarding bone lineage precursor cells is
based on experiments on human and murine bone cells, either in 2D monocultures or in vivo
(Ono et al., 2019). Similarly, the bulk of studies regarding bone formation and osteocyte, OB,
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and OC differentiation have been conducted with 2D cultures (Kim and Adachi, 2019). There are
discrepancies between bone cell types when studied in vitro in monocultures since OBs and OCs
affect one another in vivo and exhibit coupled factors and effects on signaling pathways (Kamiya
et al., 2008). While 2D cultures have broadened knowledge of cellular behavior and gene
expression, there are differences in intracellular signaling pathways compared to in vivo models
which cause distinctly different outcomes (Kim and Adachi, 2019). Therefore, data produced in
vitro in monocultures may be substantially different to data produced in this multiple cell type
3D culture. Similarly, in vitro results in 3D bone models have demonstrated different levels of
differentiation and induction of bone formation compared to in vivo systems (Blair et al., 2017).
In a study comparing 2D cocultures to 3D cocultures of osteoblastic SaOS-2 cells and THP-1derived osteoclasts by Häussling et al., it was proven that 3D coculture extended the viability and
functionality of both osteoblasts and osteoclasts. The study also demonstrated a 3D bone
coculture is more stable than a 2D culture. Häussling et al.’s study found that ALP activity
decreased slower in a 3D model compared to a 2D model. While RANKL increased at an earlier
timepoint in a 3D model compared to a 2D model, the RANKL to osteoprotegerin ration was
more stable in a 3D model. Whereas osteoclast markers decreased in the presences of high
insulin (160 I.U./l) in their 2D model, the same markers were increased in their 3D model,
namely CAII. However, some osteoclastic activity markers, such as CTSK decreased similarly in
both 2D and 3D models treated with high insulin. Notably, Häussling et al. also found
differences in mineralized matrix in the presence of OSM and high INS comparing 2D to 3D
(Häussling et al., 2021). Finally, insulin and magnesium were studied independently of each
other. A future direction for this study would be combining magnesium and insulin treatments to

36

understand the interplay between the two compounds and their joint effect on bone homeostasis
compared to their singular effects when used as individual treatments.
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